Cognitive-Behavioral Therapy vs. Supportive Psychotherapy for Adults With Body Dysmorphic Disorder (BDD)

Eligibility Criteria

Adults (age18 or older):

  • Have BDD.
  • Live within driving distance of Boston, Massachusetts.
  • Meet further qualifications for this study.
State
Massachusetts

The purpose of this study is to learn which of two forms of therapy is more likely to help people who have body dysmorphic disorder (BDD). We are comparing cognitive-behavioral therapy (CBT), which is a promising new treatment for BDD, and supportive psychotherapy (SPT), which appears to be the most widely used therapy in the community to treat BDD and related problems, such as low self-esteem or problems with family members or friends.

Study Treatments

Integrated PTSD and Smoking Treatment

Eligibility Criteria
  • Male and female patients ages 18 to 65 capable of providing informed consent
  • Willing and able to provide informed consent, attend all study visits and comply with the protocol
  •  Daily smoker for at least 3 months
  • Currently smoke an average of at least 8 cigarettes per day
  • Report a motivation to quit smoking in the next month of at least 5 on a 10-point scale
  • Meet criteria for current diagnosis of PTSD via structured clinical interview
Exclusion Criteria
  • Current diagnosis of a psychotic, eating, developmental, or bipolar disorder
  • Significant suicide risk as determined by structured interview
  • Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months
  • Limited mental competency and the inability to give informed, voluntary, written consent to participate
  • Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt
  • Current psychotherapy directed specifically toward treatment of PTSD
  • Use of other tobacco products
  • Planning on moving (outside of the immediate area) in the next 6 months
  • Insufficient command of the English language (i.e., cannot carry on a conversation with an interviewer in English or read associated text)

 

State
Texas

Research shows that people with PTSD are more likely to smoke than people without PTSD. It also shows that people with PTSD have more difficulty at attempts to quit smoking. This study is part of a program aimed at finding out how best to help smokers quit who also have PTSD.

Enhancing Panic and Smoking Reduction with D-Cycloserine

Eligibility Criteria
  • Male and female patients ages 18 to 65 capable of providing informed consent
  • Willing and able to provide informed consent, attend all study visits and comply with the protocol
  • Daily smoker for at least one year
  • Currently smoke an average of at least 10 cigarettes per day
  • Report a motivation to quit smoking in the next month of at least 5 on a 10-point scale
  • Evidence of panic attack within the past year and endorsement of smoking as an emotion regulation strategy (i.e., score at least a 78 on the SAEQ).
Exclusion Criteria
  • Subjects who do not use smoking as an emotion-regulation strategy 
  • Current diagnosis of a psychotic, eating, developmental, or bipolar disorder
  • Significant suicide risk as determined by structured interview
  • Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months)  
  • Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months
  • Current use of isoniazid or ethionamide compounds
  • A history of significant medical condition and/or be deemed as currently unhealthy in the context of a complete physical examination
  • Limited mental competency and the inability to give informed, voluntary, written consent to participate
  • Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt
  • Concurrent psychotherapy initiated within three months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of anxiety or mood disorder other than general supportive therapy initiated at least 3 months prior to the study
  • Use of other tobacco products
  • Plans to move outside of the immediate area in the next 6 months
  • Insufficient command of the English language

 

State
Texas

The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. Individuals will receive 7 weeks of panic- and smoking-reduction treatment (PSRT) and one pill of d-cycloserine (DCS) or one pill placebo one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).